|Table of Contents|

Research advances in targeted therapy and related drugs for ameloblastoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 11
Page:
2148-2155
Research Field:
Publishing date:

Info

Title:
Research advances in targeted therapy and related drugs for ameloblastoma
Author(s):
YANG Mengyuan; ZHANG Xudong
Department of Oral and Maxillofacial,Hebei Key Laboratory of Stomatology,Hebei Clinical Research Center for Oral Diseases,School and Hospital of Stomatology,Hebei Medical University,Hebei Shijiazhuang 050000,China.
Keywords:
ameloblastoma; targeted therapy; pharmaceutical applications
PACS:
R739.8
DOI:
10.3969/j.issn.1672-4992.2023.11.032
Abstract:
Ameloblastomas are common benign tumors of the oral and maxillofacial region and surgical excision is preferred for the management of this tumor.However,resection can easily cause maxillofacial deformities and loss of function,and the postoperative recurrence rate is high.Currently,there is still no effective treatment for multiple recurrences and metastases of ameloblastoma.Research hotspots for ameloblastoma treatment have focused on comprehensive treatment modalities in the form of targeted therapies combined with surgery.Over the past decade or so,with the development of molecular biology,especially molecular targets such as BRAF and SMO were discovered,related drugs such as Vemurafenib have begun to be used initially in the clinic and have achieved certain results.Research on the mechanism of action of targeted therapy can further improve the ameloblastoma cure rate and reduce recurrence and metastasis,and this article provides a review of the progress of targeted therapy targets and related drugs for ameloblastoma.

References:

[1］EFFIOM OA,OGUNDANA OM,AKINSHIPO AO,et al.Ameloblastoma:current etiopathological concepts and management［J］.Oral Dis,2018,24(3):307-316.
[2］LU YW,ZHANG XD,LI XJ.Molecular biology exploration and targeted therapy strategy of Ameloblastoma［J］.Arch Oral Biol,2022,140:105454.
[3］ANAND R,NARWAL A,PANDIAR D,et al.Clinicopathological profile of 80 cases of unicystic ameloblastoma aided by a histopathological comparison using modified philipsen-reichart classification and marx-stern classification［J］.Head Neck Pathol,2021,15(3):875-881.
[4］ANPALAGAN A,TZORTZIS A,TWIGG J,et al.Current practice in the management of peripheral ameloblastoma:a structured review［J］.Br J Oral Maxillofac Surg,2021,59(1):e1-e8.
[5］闫惠淳，王通宇，刘洁，等.成釉细胞瘤相关信号通路研究进展［J］.中国实用口腔科杂志,2018,11(11):690-694. YAN HC,WANG TY,LIU J,et al.Research progress of ameloblastoma related signal pathways ［J］.Chinese Journal of Practical Dentistry,2018,11(11):690-694.
[6］KENNEDY WR,WERNING JW,KAYE FJ,et al.Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy［J］.Eur Arch Otorhinolaryngol,2016,273(10):3293-3297.
[7］STINE ZE,SCHUG ZT,SALVINO JM,et al.Targeting cancer metabolism in the era of precision oncology［J］.Nat Rev Drug Discov,2022,21(2):141-162.
[8］MERLA A,LIU KG,RAJDEV L.Targeted therapy in biliary tract cancers［J］.Curr Treat Options Oncol,2015,16(10):48.
[9］LEE YT,TAN YJ,OON CE.Molecular targeted therapy:Treating cancer with specificity［J］.Eur J Pharmacol,2018,834:188-196.
[10］DONG JK,LEI HM,LIANG Q,et al.Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase［J］.Theranostics,2018,8(7):1808-1823.
[11］VASUDEV NS,REYNOLDS AR.Anti-angiogenic therapy for cancer:current progress,unresolved questions and future directions［J］.Angiogenesis,2014,17(3):471-494.
[12］李海丽，邵驰浩，周若宇，等.抑癌基因与癌基因的最新研究进展［J］.基础医学与临床,2018,38(07):1029-1033. LI HL,SHAO CH,ZHOU RY,et al The latest research progress of tumor suppressor gene and oncogene ［J］.Basic Medicine and Clinical Medicine,2018,38(07):1029-1033.
[13］ZHAO J,LUO Z.Discovery of raf family is a milestone in deciphering the ras-mediated intracellular signaling pathway［J］.Int J Mol Sci,2022,23(9):5158.
[14］ADAMS R,COUMBE J,COUMBE B,et al.BRAF inhibitors and their immunological effects in malignant melanoma［J］.Expert Rev Clin Immunol,2022,18(4):347-362.
[15］IMYANITOV EN,IYEVLEVA AG,LEVCHENKO EV.Molecular testing and targeted therapy for non-small cell lung cancer:Current status and perspectives［J］.Crit Rev Oncol Hematol,2021,157:103194.
[16］RODRIGUEZ-GALINDO C,ALLEN CE.Langerhans cell histiocytosis［J］.Blood,2020,135(16):1319-1331.
[17］BILLER LH,SCHRAG D.Diagnosis and treatment of metastatic colorectal cancer:A review［J］.JAMA,2021,325(7):669-685.
[18］ABDULLAH MI,JUNIT SM,NG KL,et al.Papillary thyroid cancer:Genetic alterations and molecular biomarker investigations［J］.Int J Med Sci,2019,16(3):450-460.
[19］DI NICOLANTONIO F,VITIELLO PP,MARSONI S,et al.Precision oncology in metastatic colorectal cancer-from biology to medicine［J］.Nat Rev Clin Oncol,2021,18(8):506-525.
[20］BROWN NA,ROLLAND D,MCHUGH JB,et al.Activating FGFR2-RAS-BRAF mutations in ameloblastoma［J］.Clin Cancer Res,2014,20(21):5517-5526.
[21］SWEENEY RT,MCCLARY AC,MYERS BR,et al.Identification of recurrent SMO and BRAF mutations in ameloblastomas［J］.Nat Genet,2014,46(7):722-725.
[22］KURPPA KJ,CATON J,MORGAN PR,et al.High frequency of BRAFV600E mutations in ameloblastoma［J］.J Pathol,2014,232(5):492-498.
[23］PEREIRA NB,PEREIRA KM,COURA BP,et al.BRAFV600E mutation in the diagnosis of unicystic ameloblastoma［J］.J Oral Pathol Med,2016,45(10):780-785.
[24］BRUNNER P,BIHL M,JUNDT G,et al.BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology［J］.Oral Oncol,2015,51(10):e77-e78.
[25］张旭东.成釉细胞瘤BRAF、SMO、RECK基因突变与其生物学行为的关系［D］.石家庄：河北医科大学,2016. ZHANG XD.Relationship between BRAF,SMO,RECK gene mutation and biological behavior in ameloblastoma ［D］.Shijiazhuang:Hebei Medical University,2016.
[26］DINIZ MG,GOMES CC,GUIMARAES BV,et al.Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours［J］.Tumour Biol,2015,36(7):5649-5653.
[27］COURA BP,BERNARDES VF,DE SOUSA SF,et al.KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features［J］.Mod Pathol,2019,32(6):799-806.
[28］KONDO S,OTA A,ONO T,et al.Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma［J］.Cancer Med,2020,9(8):2904-2917.
[29］COX AD,FESIK SW,KIMMELMAN AC,et al.Drugging the undruggable RAS:Missionpossible［J］.Nat Rev Drug Discov,2014,13(11):828-851.
[30]JANES MR,ZHANG J,LI LS,et al.Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor［J］.Cell,2018,172(3):578-589.
[31]NAGASAKA M,POTUGARI B,NGUYEN A,et al.KRAS inhibitors- yes but what next? Direct targeting of KRAS- vaccines,adoptive T cell therapy and beyond［J］.Cancer Treat Rev,2021,101:102309.
[32］ARDALAN B,AZQUETA J,SLEEMAN D.Cobimetinib plus gemcitabine:An active combination in KRAS G12R-mutated pancreatic ductal adenocarcinoma patients in previously treated and failed multiple chemotherapies［J］.J Pancreat Cancer,2021,7(1):65-70.
[33]NOVAK D,HUSER L,ELTON JJ,et al.SOX2 in development and cancer biology［J］.Semin Cancer Biol,2020,67(Pt 1):74-82.
[34］PHATTARATARATIP E,PANITKUL T,KHODKAEW W,et al.Expression of SOX2 and OCT4 in odontogenic cysts and tumors［J］.Head Face Med,2021,17(1):29.
[35］CHIH-HUANG TSENG,PEI-HSUAN LU,YI-PING WANG,et al.Enrichment of SOX2-positive cells in BRAFV600E mutated and recurrent ameloblastoma［J］.Journal of Personalized Medicine,2022,12(1):77.
[36]钟鸣,刘敬东,王洁,等.hTERT、c-fos、c-jun在成釉细胞瘤中的表达及意义［J］.上海口腔医学,2006,15(05):461-465. ZHONG M,LIU JD,WANG J,et al.Expression and significance of hTERT,c-fos and c-jun in ameloblastoma［J］.Shanghai Journal of Stomatology,2006,15(5):461-465.
[37］HEIKINHEIMO K,JEE KJ,NIINI T,et al.Gene expression profiling of ameloblastoma and human tooth germ by means of a cDNA microarray［J］.J Dent Res,2002,81(8):525-530.
[38］SALVATORELLI L,PARENTI R,LEONE G,et al.Wilms tumor 1(WT1) protein:Diagnostic utility in pediatric tumors［J］.Acta Histochem,2015,117(4-5):367-378.
[39］BOLOGNA-MOLINA R,TAKEDA Y,KUGA T,et al.Expression of Wilms' tumor 1(WT1) in ameloblastomas［J］.J Oral Sci,2016,58(3):407-413.
[40］KHALELE BA,AL-SHIATY RA.A novel marker of ameloblastoma and systematic review of immunohistochemical findings［J］.Ann Diagn Pathol,2016,22:18-24.
[41]DEGIRMENCI U,WANG M,HU J.Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy［J］.Cells,2020,9(1):198.
[42］LIANG QX,LIANG YC,XU ZY,et al.RECK overexpression reduces invasive ability in ameloblastoma cells［J］.J Oral Pathol Med,2014,43(8):613-618.
[43］KUMAMOTO H,OOYA K.Immunohistochemical detection of MT1-MMP,RECK,and EMMPRIN in ameloblastic tumors［J］.J Oral Pathol Med,2006,35(6):345-351.
[44］ZHANG X,WANG J,LIU H,et al.The clinicopathologic relevance of RECK gene polymorphisms in ameloblastoma［J］.Arch Oral Biol,2017,79:77-86.
[45］WANG Y,HUANG P,HU Y,et al.An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model［J］.Acta Biochim Biophys Sin(Shanghai),2021,53(6):766-774.
[46］USAMI Y,ITO A,OHNUMA K,et al.Tumor suppressor in lung cancer-1 as a novel ameloblast adhesion molecule and its downregulation in ameloblastoma［J］.Pathol Int,2007,57(2):68-75.
[47］S SIRIWARDENA,Y KUDO,I OGAWA,et al.Aberrant beta-catenin expression and adenomatous polyposis coli gene mutation in ameloblastoma and odontogenic carcinoma［J］.Oral Oncology,2009,45(2):103-108.
[48］SCHEFFEL RS,DORA JM,MAIA AL.BRAF mutations in thyroid cancer［J］.Curr Opin Oncol,2022,34(1):9-18.
[49］SANDRA F,HARADA H,NAKAMURA N,et al.Midkine induced growth of ameloblastoma through MAPK and Akt pathways［J］.Oral Oncol,2004,40(3):274-280.
[50］WRIGHT JM,VERED M.Update from the 4th edition of the world health organization classification of head and neck tumours:Odontogenic and maxillofacial bone tumors［J］.Head Neck Pathol,2017,11(1):68-77.
[51］SKODA AM,SIMOVIC D,KARIN V,et al.The role of the Hedgehog signaling pathway in cancer:A comprehensive review［J］.Bosn J Basic Med Sci,2018,18(1):8-20.
[52]CHAI JY,SUGUMAR V,ALSHAWSH MA,et al.The role of smoothened-dependent and-independent hedgehog signaling pathway in tumorigenesis［J］.Biomedicines,2021,9(9):1188.
[53］KUMAMOTO H,OHKI K,OOYA K.Expression of Sonic hedgehog(SHH) signaling molecules in ameloblastomas［J］.J Oral Pathol Med,2004,33(3):185-190.
[54］MISHRA P,PANDA A,BANDYOPADHYAY A,et al.Sonic hedgehog signalling pathway and ameloblastoma-a review［J］.J Clin Diagn Res,2015,9(11):E10-E13.
[55]HASSANEIN AM,GLANZ SM,KESSLER HP,et al.Beta-Catenin is expressed aberrantly in tumors expressing shadow cells.Pilomatricoma,craniopharyngioma,and calcifying odontogenic cyst［J］.Am J Clin Pathol,2003,120(5):732-736.
[56]DANIELSON KG,PILLARISETTI J,COHEN IR,et al.Characterization of the complete genomic structure of the human WNT-5A gene,functional analysis of its promoter,chromosomal mapping,and expression in early human embryogenesis［J］.J Biol Chem,1995,270(52):31225-31234.
[57]SUKARAWAN W,SIMMONS D,SUGGS C,et al.WNT5A expression in ameloblastoma and its roles in regulating enamel epithelium tumorigenic behaviors［J］.Am J Pathol,2010,176(1):461-471.
[58］SIAR CH,NAGATSUKA H,HAN PP,et al.Differential expression of canonical and non-canonical Wnt ligands in ameloblastoma［J］.J Oral Pathol Med,2012,41(4):332-339.
[59］BRUNET M,KHALIFA E,ITALIANO A.Enabling precision medicine for rare head and neck tumors:The example of BRAF/MEK targeting in patients with metastatic ameloblastoma［J］.Front Oncol,2019,9:1204.
[60］MORGANE BROUDIC-GUIBERT,JEAN-YVES BLAY,LEA VAZQUEZ,et al.Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation:a case report［J］.Journal of Medical Case Reports,2019,13(1):245.
[61］FERNANDES GS,GIRARDI DM,BERNARDES J,et al.Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation［J］.BMC Cancer,2018,18(1):887.
[62］FADEN D,ALGAZI A.Durable treatment of ameloblastoma with single agent BRAFi Re:Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma［J］.J Natl Cancer Inst,2017,109(1):djw190.
[63］KAYE FJ,IVEY AM,DRANE WE,et al.Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma［J］.J Natl Cancer Inst,2015,107(1):378.
[64］ABRAMSON Z,DAYTON OL,DRANE WE,et al.Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition:A case report with 8-year clinical follow-up［J］.Oral Oncol,2022,128:105854.
[65］TAN S,POLLACK JR,KAPLAN MJ,et al.BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response［J］.Oral Surg Oral Med Oral Pathol Oral Radiol,2016,122(1):e5-e7.
[66]GUSTAVO SF,DANIEL MG,JOAO PAULO GB,et al.Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation［J］.BMC Cancer,2018,18(1):887.
[67］LARKIN J,ASCIERTO PA,DRENO B,et al.Combined vemurafenib and cobimetinib in BRAF-mutated melanoma［J］.N Engl J Med,2014,371(20):1867-1876.
[68］何优雅，季彤.SMO基因突变在成釉细胞瘤中的研究进展［J］.国际口腔医学杂志,2020,47(01):63-67. HE YY,JI T.Research progress of SMO gene mutation in ameloblastoma ［J］International Journal of Stomatology,2020,47(01):63-67.
[69]HOY SM.Glasdegib:First global approval［J］.Drugs,2019,79(2):207-213.
[70］BRANCACCIO G,PEA F,MOSCARELLA E,et al.Sonidegib for the treatment of advanced basal cell carcinoma［J］.Front Oncol,2020,10:582866.
[71］DUMMER R,ASCIERTO PA,BASSET-SEGUIN N,et al.Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma:a joint expert opinion［J］.J Eur Acad Dermatol Venereol,2020,34(9):1944-1956.
[72］HARRISON ZHU,DANIEL J LEWIS.Topical hedgehog inhibitors for basal cell carcinoma:how far away are we［J］.Expert Opinion on Pharmacotherapy,2022,23(6):739-740.
[73］HONGYI AS,CHEE WB,CHONG TK,et al.Ameloblastoma:A succinct review of the classification,genetic understanding and novel molecular targeted therapies［J］.Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland,2021,19(4):238-243.
[74]SAUK JJ,NIKITAKIS NG,SCHEPER MA.Are we on the brink of nonsurgical treatment for ameloblastoma［J］.Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2010,110(1):68-78.
[75］ZOI V,GALANI V,LIANOS GD,et al.The role of curcumin in cancer treatment［J］.Biomedicines,2021,9(9):1086.
[76］MORGADO S,RAMOS NV,FREITAS F,et al.Mycolicibacterium fortuitum genomic epidemiology,resistome and virulome［J］.Mem Inst Oswaldo Cruz,2022,116:e210247.
[77］COLLI LM,MACHIELA MJ,ZHANG H,et al.Landscape of combination immunotherapy and targeted therapy to improve cancer management［J］.Cancer Res,2017,77(13):3666-3671.

Memo

Memo:
河北省自然科学基金项目（编号：H2021206165）
Last Update: 2023-04-28